Eric Keller
Co-founder, CEO & DirectorMr. Eric Keller, J.D., is CEO, Founder & Director of Retension Pharmaceuticals, Inc. from July 2023. Mr. Keller was President & Director of Retension Pharmaceuticals, Inc. He is a proven business and legal executive with an experience in life sciences-based companies. He is the Founder and CEO of Redux Therapeutics. He is co-founder and director of Response Pharmaceuticals, Inc. (“Response”); and co-founder, CEO and director of Restor Pharmaceuticals, Inc. (“Restor”). As CEO of Nano Terra, a Boston-based nanotechnology company, he led the acquisition of Surface Logix and the subsequent out-license of three Phase 2 small molecule drugs, including RezuRock, now owned and marketed by Sanofi and RTN-001. He is also the Co-Founder and Head of Strategy at C2Sense, an MIT-based medical diagnostic company and is the Executive Vice President of SGH2 Energy Global, a developer and operator of biogenic waste-to-green hydrogen projects. Mr. Keller serves as acting President and a director of Noveome Biotherapeutics, Inc. He served as Strategic Advisor and Chief Business Officer of SipNose, an Israeli company focused on direct nose-to-brain delivery of drugs for a variety of CNS disorders. Mr. Keller received his A.B. from Harvard College and J.D. from Boston College Law School.
Positions
- Company NameRetension Pharmaceuticals, Inc.Stock CodeRTSNPositionCo-founder, CEO & DirectorColleagues
- MJMichael Joseph BerendtExecutive Chairman
- PSPaul SweetnamCo-Founder, Chief Scientific Officer & Secretary
- ADAlexander Duke SchwartzChief Financial Officer
- SBSabine BissonChief Operations Officer
- DJDonald John OldsIndependent Director
- FMFranklin M. BergerIndependent Director
- OAOmar Al DhaybiMember of Scientific Advisory Board
